{"id":"lymphodepletion-conditioning","safety":{"commonSideEffects":[{"rate":"50-80%","effect":"Neutropenia"},{"rate":"30-60%","effect":"Thrombocytopenia"},{"rate":"20-50%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This process is typically used in the treatment of various blood cancers and disorders, such as leukemia and lymphoma. The goal of lymphodepletion is to reduce the immune system's ability to reject the transplanted cells, allowing them to engraft and produce healthy blood cells.","oneSentence":"Lymphodepletion conditioning involves the use of chemotherapy or radiation to deplete the immune system, making it more receptive to stem cell or bone marrow transplants.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:58:57.907Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autologous hematopoietic stem cell transplantation for multiple myeloma"},{"name":"Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia"}]},"trialDetails":[{"nctId":"NCT06060613","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Obsidian Therapeutics, Inc.","startDate":"2023-10-25","conditions":"Tumor Skin, Metastatic Melanoma, Melanoma","enrollment":208},{"nctId":"NCT07490275","phase":"PHASE1","title":"Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis, Refractory / Relapsing / Progressive Inflammatory Myopathy","enrollment":9},{"nctId":"NCT06150651","phase":"PHASE1","title":"Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2023-12-01","conditions":"SLE (Systemic Lupus)","enrollment":3},{"nctId":"NCT06913608","phase":"PHASE1","title":"A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases","status":"WITHDRAWN","sponsor":"Calibr, a division of Scripps Research","startDate":"2026-03","conditions":"Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)","enrollment":""},{"nctId":"NCT06138132","phase":"PHASE1","title":"A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-04-10","conditions":"Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive","enrollment":12},{"nctId":"NCT07420010","phase":"EARLY_PHASE1","title":"An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.","status":"NOT_YET_RECRUITING","sponsor":"Weijia Fang, MD","startDate":"2026-03-15","conditions":"Ovarian Cancer, Mesothelioma, Colon Cancer","enrollment":24},{"nctId":"NCT07061938","phase":"PHASE1, PHASE2","title":"Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease","status":"RECRUITING","sponsor":"Acepodia Biotech, Inc.","startDate":"2026-01-01","conditions":"IgG4 Related Disease","enrollment":30},{"nctId":"NCT06325748","phase":"PHASE1","title":"SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Senti Biosciences","startDate":"2024-04-22","conditions":"AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies","enrollment":21},{"nctId":"NCT07406724","phase":"PHASE2","title":"HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Qingdao Sino-Cell Biomedicine Co., Ltd.","startDate":"2026-02-26","conditions":"Melanoma (Excluding Uveal Melanoma)","enrollment":90},{"nctId":"NCT06646627","phase":"PHASE1","title":"Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-11-11","conditions":"Ovarian Cancer","enrollment":48},{"nctId":"NCT06193889","phase":"PHASE2, PHASE3","title":"KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Kyverna Therapeutics","startDate":"2024-08-28","conditions":"Myasthenia Gravis, Generalized Myasthenia Gravis","enrollment":66},{"nctId":"NCT04196413","phase":"PHASE1","title":"GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2020-06-04","conditions":"Glioma of Spinal Cord, Glioma of Brainstem","enrollment":97},{"nctId":"NCT06464965","phase":"PHASE1","title":"Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer","status":"COMPLETED","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2024-07-03","conditions":"Gastric Cancer, Pancreas Adenocarcinoma","enrollment":10},{"nctId":"NCT06588491","phase":"PHASE2","title":"KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyverna Therapeutics","startDate":"2024-09-25","conditions":"Stiff-Person Syndrome, SPS","enrollment":25},{"nctId":"NCT05950802","phase":"PHASE1","title":"Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-07-14","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":40},{"nctId":"NCT06544330","phase":"PHASE1","title":"A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Synthekine","startDate":"2025-04-29","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis","enrollment":48},{"nctId":"NCT05938725","phase":"PHASE1, PHASE2","title":"KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyverna Therapeutics","startDate":"2023-04-28","conditions":"Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV","enrollment":6},{"nctId":"NCT03396575","phase":"PHASE1","title":"Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-07-17","conditions":"Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma","enrollment":11},{"nctId":"NCT06342960","phase":"PHASE1, PHASE2","title":"KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyverna Therapeutics","startDate":"2022-12-01","conditions":"Lupus Nephritis, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV","enrollment":2},{"nctId":"NCT06400303","phase":"PHASE1, PHASE2","title":"KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyverna Therapeutics","startDate":"2024-08-06","conditions":"Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria","enrollment":3},{"nctId":"NCT06347718","phase":"PHASE1, PHASE2","title":"CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease","status":"RECRUITING","sponsor":"Miltenyi Biomedicine GmbH","startDate":"2023-07-17","conditions":"Systemic Lupus Erythematosus, Systemic Sclerosis, Dermatomyositis","enrollment":24},{"nctId":"NCT05667506","phase":"PHASE1, PHASE2","title":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)","status":"RECRUITING","sponsor":"Juventas Cell Therapy Ltd.","startDate":"2023-02-07","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":47},{"nctId":"NCT06343376","phase":"PHASE1","title":"Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-11-26","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma","enrollment":1},{"nctId":"NCT03937544","phase":"PHASE2, PHASE3","title":"Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL","status":"RECRUITING","sponsor":"National University of Malaysia","startDate":"2019-03-19","conditions":"Relapsed B Acute Lymphoblastic Leukaemia, Refractory B Acute Lymphoblastic Leukaemia","enrollment":10},{"nctId":"NCT06421701","phase":"PHASE1","title":"Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-08-01","conditions":"Systemic Lupus Erythematosus","enrollment":10},{"nctId":"NCT05972720","phase":"PHASE2","title":"A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma","status":"TERMINATED","sponsor":"CARGO Therapeutics","startDate":"2023-08-01","conditions":"Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)","enrollment":101},{"nctId":"NCT03054298","phase":"PHASE1","title":"CAR T Cells in Mesothelin Expressing Cancers","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-04-06","conditions":"Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma","enrollment":65},{"nctId":"NCT04088864","phase":"PHASE1","title":"CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","startDate":"2020-01-10","conditions":"B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma","enrollment":10},{"nctId":"NCT04032847","phase":"PHASE1, PHASE2","title":"ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC","status":"TERMINATED","sponsor":"Achilles Therapeutics UK Limited","startDate":"2019-07-08","conditions":"Advanced Non Small Cell Lung Cancer","enrollment":27},{"nctId":"NCT06384976","phase":"PHASE2","title":"KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyverna Therapeutics","startDate":"2024-09-20","conditions":"Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis","enrollment":120},{"nctId":"NCT06003179","phase":"PHASE1","title":"Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2024-04-05","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":""},{"nctId":"NCT05128786","phase":"PHASE1","title":"CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas","status":"TERMINATED","sponsor":"Shanghai PerHum Therapeutics Co., Ltd.","startDate":"2021-12-30","conditions":"SAR","enrollment":9},{"nctId":"NCT03393936","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma","status":"TERMINATED","sponsor":"Shanghai PerHum Therapeutics Co., Ltd.","startDate":"2018-03-26","conditions":"Renal Cell Carcinoma","enrollment":66},{"nctId":"NCT03960060","phase":"PHASE1","title":"A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors","status":"TERMINATED","sponsor":"Shanghai PerHum Therapeutics Co., Ltd.","startDate":"2019-05-16","conditions":"Solid Tumor, Soft Tissue Sarcoma, Gastric Cancer","enrollment":9},{"nctId":"NCT04511871","phase":"PHASE1","title":"A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai PerHum Therapeutics Co., Ltd.","startDate":"2020-07-09","conditions":"Solid Tumor, Gastric Cancer, Breast Cancer","enrollment":12},{"nctId":"NCT06642025","phase":"EARLY_PHASE1","title":"EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Zhimin Zhai","startDate":"2024-09-01","conditions":"Acute Myeloid Leukemia (AML), CAR-T","enrollment":9},{"nctId":"NCT06367114","phase":"PHASE2","title":"Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","startDate":"2024-04","conditions":"Relapsed or Refractory Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT04173988","phase":"EARLY_PHASE1","title":"Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2020-01-09","conditions":"ALL, Childhood B-Cell","enrollment":6},{"nctId":"NCT06196658","phase":"EARLY_PHASE1","title":"Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhang Xiaofeng,MD","startDate":"2024-01-01","conditions":"Pancreatic Cancer, Advanced Biliary Cancer","enrollment":6},{"nctId":"NCT04812691","phase":"PHASE1","title":"CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","startDate":"2020-07-10","conditions":"Diffuse Large B Cell Lymphoma","enrollment":12},{"nctId":"NCT04825496","phase":"PHASE1","title":"Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","startDate":"2021-04-09","conditions":"Relapsed or Refractory Acute Lymphoblastic Leukemia","enrollment":18},{"nctId":"NCT05768529","phase":"PHASE1, PHASE2","title":"Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","startDate":"2023-03-28","conditions":"Relapsed or Refractory Non-Hodgkin's Lymphoma","enrollment":100},{"nctId":"NCT05776407","phase":"PHASE1, PHASE2","title":"Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma","status":"UNKNOWN","sponsor":"Chongqing University Cancer Hospital","startDate":"2023-05","conditions":"Refractory or Relapsed B Cell Lymphoma","enrollment":12},{"nctId":"NCT05727683","phase":"PHASE1","title":"CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","startDate":"2022-04-28","conditions":"Acute Lymphocytic Leukemia","enrollment":33},{"nctId":"NCT04030195","phase":"PHASE1, PHASE2","title":"Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL","status":"COMPLETED","sponsor":"Precision BioSciences, Inc.","startDate":"2020-03-24","conditions":"Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory","enrollment":18},{"nctId":"NCT05691153","phase":"PHASE1","title":"ThisCART19A for B-NHL Relapsed After Auto-CAR T","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-12-01","conditions":"CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT05679687","phase":"PHASE1","title":"ThisCART19A Bridging to alloHSCT for R/R B-ALL","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-12-01","conditions":"CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL","enrollment":20},{"nctId":"NCT04844086","phase":"PHASE1","title":"RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies","status":"TERMINATED","sponsor":"Eden BioCell Ltd.","startDate":"2021-03-02","conditions":"B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory","enrollment":2},{"nctId":"NCT05208853","phase":"EARLY_PHASE1","title":"An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2022-02-10","conditions":"Hodgkin Lymphoma, NK/T Cell Lymphoma, Peripheral T Cell Lymphoma, Unspecified","enrollment":9},{"nctId":"NCT00076752","phase":"PHASE2","title":"Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-01-30","conditions":"Lupus Erythematosus, Systemic","enrollment":9},{"nctId":"NCT03380039","phase":"NA","title":"Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2017-10-13","conditions":"Refractory or Relapsed Multiple Myeloma","enrollment":6},{"nctId":"NCT03302403","phase":"NA","title":"Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors","status":"UNKNOWN","sponsor":"Kang YU","startDate":"2017-12-29","conditions":"B Cell Lymphoma, B Cell Leukemia, Myeloma","enrollment":18},{"nctId":"NCT03716856","phase":"PHASE1","title":"Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2018-03-23","conditions":"Refractory or Relapsed Multiple Myeloma","enrollment":11},{"nctId":"NCT03146234","phase":"NA","title":"CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2017-03-17","conditions":"Hepatocellular Carcinoma","enrollment":7},{"nctId":"NCT03344367","phase":"PHASE1","title":"Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Peking University","startDate":"2017-11-16","conditions":"Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT03355859","phase":"PHASE1","title":"Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Zhao Weili","startDate":"2018-01-05","conditions":"Non Hodgkin Lymphoma","enrollment":10},{"nctId":"NCT03159819","phase":"NA","title":"Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2017-04-01","conditions":"Advanced Gastric Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Lymphodepletion Conditioning","genericName":"Lymphodepletion Conditioning","companyName":"Qingdao Sino-Cell Biomedicine Co., Ltd.","companyId":"qingdao-sino-cell-biomedicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lymphodepletion conditioning involves the use of chemotherapy or radiation to deplete the immune system, making it more receptive to stem cell or bone marrow transplants. Used for Autologous hematopoietic stem cell transplantation for multiple myeloma, Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}